Click here for NICC Library Webpage
Click here for NICC Library Webpage
 Search 
 My Account 
 ID Information 
 Calmar New Materials 
 Peosta New Materials 
   
Advanced AlphabeticalBasicHistory
Search:    Refine Search  
> You're searching: Northeast Iowa Community College
 
Item Information
 HoldingsHoldings
 
 
 More by this author
 
  •  
  • Carreyrou, John, author.
     
     Subjects
     
  •  
  • Holmes, Elizabeth, 1984-
     
  •  
  • Theranos (Firm) -- History.
     
  •  
  • Hematologic equipment industry -- United States.
     
  •  
  • New business enterprises -- Corrupt practices -- United States -- Cases.
     
  •  
  • Securities fraud -- United States. -- Cases.
     
     Browse Catalog
      by author:
     
  •  
  •  Carreyrou, John, author.
     
      by title:
     
  •  
  •  Bad blood : secrets ...
     
     
     
     MARC Display
    Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.
    by Carreyrou, John, author.
    New York : Alfred A. Knopf, 2018
    Description: 
    x, 339 pages ; 25 cm
    Edition: 
    First edition.
    Contents: 
    A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue.
    Summary: 
    "In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley." -- Publisher's description
    The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.
    Add to my list 
    Copy/Holding information
    LocationCollectionCall No.CopyStatus 
    Calmar Campus LibraryCirculation Stacks (Calmar)338.7 Car2018Checked InAdd Copy to MyList

    Format:HTMLPlain textDelimited
    Subject: 
    Email to:


    Horizon Information Portal 3.25_9807
     Powered by SirsiDynix
    © 2001-2013 SirsiDynix All rights reserved.
    Horizon Information Portal